Northrop Grumman Corporation 10-Qquarter ended 2026-09-30

Executive Summary

Northrop Grumman sells military aircraft, weapons, electronics and space systems, earning revenue primarily through U.S. government contracts. It is expanding strategic-deterrence programs, particularly B-21 bomber production and Sentinel missile development, while investing in production capacity. Backlog grew 15% to $110B, strengthening future demand visibility, but quarterly sales growth translated into only modest profit growth. For investors, the opportunity is converting these programs into sustained production; the threat is that cost overruns, unsettled contract terms and upfront investment consume the returns.

What's Happening in the Business

• B-21 expansion: An Air Force agreement increases production capacity and rates, with Northrop expecting ≈$2.5B of investment over multiple years. Management sees potential for better returns, but future production-lot quantities and pricing remain unsettled. Selling a previously planned company-owned test aircraft to the Air Force accelerated initial-production deliveries without increasing the expected aircraft count.
• Sentinel ramp: Further definition of the execution plan added $9.4B to backlog. The current development contract reimburses allowable costs, but later phases remain unpriced and unnegotiated, leaving the economics of the broader rollout unresolved.
• Portfolio demand: F-35 materials timing and sustainment supported Aeronautics growth; Sentinel and tactical rocket motors lifted Defense Systems. Restricted airborne-radar and space programs also expanded, while lower advanced-microelectronics volume and commercial resupply launch timing offset some growth. Service revenue declined partly because of the prior-year training-services divestiture.
• Orders and funding: Q3 net awards of $16.4B exceeded sales, including restricted programs, Sentinel and Virginia-class submarines. The order pipeline is expanding, but more than half of backlog is unfunded and depends on future appropriations.

Key Financial Highlights

• Contract-estimate changes: Favorable cumulative contract-estimate adjustments contributed $221M to Q3 operating income vs $81M, materially supporting profit. Earlier unfavorable adjustments affected B-21, GEM 63XL and the Stand-in Attack Weapon.
• Comparability: Nine-month segment improvement largely reflected the prior-year B-21 loss provision. Consolidated comparisons also included a prior-year $231M divestiture gain and a smaller adjustment between financial-accounting and government-contract pension costs.
• Tax benefits: Nine-month research-credit benefits totaled $356M, including a $115M remeasurement benefit. These helped lower the effective tax rate to 11.5% from 17.2%; that earnings uplift is not operating improvement.
• Cash conversion: Nine-month OCF of $1.37B trailed net earnings of $3.09B, with $2.15B of trade working-capital outflows. Capital expenditures of $775M left FCF of $594M. Management’s adjusted FCF of $965M additionally includes the $371M customer equipment sale; lower cash taxes drove most of the OCF improvement.
• Capital returns: Dividends of $1.04B exceeded conventional FCF. Repurchases fell to $68M from $1.17B, and period-end shares outstanding were broadly unchanged at 142M, so buybacks did not shrink the share count.

Risk Assessment

• Program economics: B-21 initial production has accumulated ≈$2.0B of losses, with $1.0B of loss accrual remaining; supplier costs, execution and unsettled future pricing could absorb expansion benefits.
• Federal funding concentration: The U.S. government supplied 85% of quarterly sales, and the continuing resolution through 12/11/2026 could delay new starts and payments despite substantial backlog.
• Fixed-price exposure: Fixed-price contracts reached 53% of quarterly sales; inflation, supplier constraints and schedule slippage can leave Northrop bearing costs it cannot recover.
• Legal and environmental exposure: Bethpage remediation accruals were $554M, with another $403M of reasonably possible costs; unresolved pension-cost civil and contract-administration matters add unquantified exposure.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

What to Watch

• B-21 production economics: Capacity expansion is proceeding despite accumulated losses. Later filings should show whether deliveries and negotiated pricing improve returns or require additional loss provisions.
• Sentinel execution: The backlog increase supports growth, but later phases remain unsettled. Progress means development milestones and negotiated follow-on work; setbacks mean schedule changes or adverse cost estimates.
• Mission Systems demand: Radar growth is offsetting weaker advanced microelectronics. Broader volume growth and recovering margins would strengthen the story; continued profit declines would weaken it.
• Cash conversion: Working capital is absorbing cash as production expands. Watch whether customer collections support investment and dividends without further cash depletion or borrowing.